R&D channel feed

Pfiz­er picks GLP-1 tablet win­ner: Danuglipron for PhI­II

Last year
Pharma

Ex­clu­sive: The se­cret to de­sign­ing pro­tein drugs with AI? Gen­er­ate be­lieves it's cryo-EM at un­prece­dent­ed scale

Last year
AI
Discovery

No­vo Nordisk's oral semaglu­tide on par with in­jectable ver­sion in weight loss and safe­ty

Last year

Moon­Lake's PhII da­ta on skin dis­ease set it up against Cosen­tyx, UCB and oth­ers in IL-17 field

Last year

Ver­tex's cell ther­a­py gives ear­ly hope for wean­ing some type 1 di­a­betes pa­tients from in­sulin

Last year

CAR-T cell ther­a­py for myas­the­nia gravis shows promise in small study by Carte­sian Ther­a­peu­tics

Last year
Cell/Gene Tx

Roche stops de­vel­op­ment on an An­gel­man ther­a­py due to dis­ap­point­ing ef­fi­ca­cy, says it’s seek­ing ex­ter­nal part­ner

Last year
Pharma

Aslan out­li­cens­es atopic der­mati­tis an­ti­body in $138.5M deal

Last year
Deals

As Roivant read­ies for a UC clash with Mer­ck, CEO Matt Gline is can­did about keep­ing a com­pet­i­tive edge

Last year

Trail­ing Akero and 89bio, Boston Phar­ma­ceu­ti­cals posts ear­ly da­ta on its NASH in­jec­tion

Last year

UniQure un­veils mixed Hunt­ing­ton's gene ther­a­py da­ta, shares tank

Last year

GSK, Pfiz­er present key dura­bil­i­ty da­ta for RSV shots, as CDC pan­el scru­ti­nizes ri­val vac­cines

Last year

As­traZeneca stops PhI­Ia tri­al of in­haled asth­ma drug with Pieris, cra­ter­ing the Boston biotech's shares

Last year

Flag­ship start­up Em­press Ther­a­peu­tics launch­es to search for small mol­e­cule drug leads in mi­cro­bial DNA

Last year
Financing
Startups

De­nali claims a neu­ro­fil­a­ment vic­to­ry in Hunter syn­drome, two years af­ter let­ting down Wall Street

Last year

Lil­ly inks $2.4B cash deal to buy DICE and its im­munol­o­gy pipeline

Last year
Deals

Bavar­i­an Nordic's pur­chase of Emer­gen­t's late-stage Chikun­gun­ya vac­cine pays off in PhI­II read­out

Last year

Ar­cel­lx's cell ther­a­py is on hold af­ter pa­tient death in mul­ti­ple myelo­ma tri­al

Last year
Cell/Gene Tx

As­traZeneca scraps oral GLP-1 af­ter PhI ‘does not meet that am­bi­tion’ of trump­ing the com­pe­ti­tion

Last year
Pharma

F2G gets re­ject­ed by the FDA, which wants more da­ta be­fore it will ap­prove an­ti­fun­gal drug, com­pa­ny says

Last year
FDA+

Rhythm’s Im­civree shows off con­tin­ued BMI de­crease in rare obe­si­ty con­di­tion

Last year

Mer­ck clos­es $10.8B deal with Prometheus

Last year

Eli Lil­ly’s mi­graine pre­ven­tion drug Em­gal­i­ty not su­pe­ri­or to Pfiz­er’s Nurtec ODT in head-to-head

Last year
Pharma

Keytru­da com­bi­na­tion hits pri­ma­ry end­point in a rare form of gas­tric can­cer

Last year
First page Previous page 81828384858687 Next page Last page
A service from the Financial Times